Treatment Of Relapsing Remitting Multiple Sclerosis

EDM number 1954 in 2006-07, proposed by Howard Stoate on 18/07/2007.

That this House welcomes the decision of the National Institute for Health and Clinical Excellence (NICE) to issue its final appraisal determination to the NHS in England and Wales recommending the use of natalizumab for patients with highly active relapsing remitting multiple sclerosis (MS); notes that MS is the most common disabling neurological condition affecting young adults, which affects an estimated 86,000 people in the UK; further notes that although there is no cure for MS, there is now a range of effective treatments which can ameliorate symptoms, slow down the progression of the disease and allow many patients to be free from all measures of disease activity for longer periods of time; and calls upon all primary care trusts to implement NICE's recommendations in full to ensure that eligible MS patients with highly active disease receive timely access to natalizumab.

This motion has been signed by a total of 56 MPs.